ABIOMED's Impella RP Bags CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:50PM CDT
Shares of ABIOMED climbed 2.8% following the announcement last week, to close at $24.48 till the last closing date.
Accuray Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 1:50PM CDT
Accuray's year-over-year loss narrowed primarily due to robust top-line improvement of 20% from the year-ago period.
Balanced View of Luminex Corporation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 5:30PM CDT
Luminex is optimistic about the life science research market and foresees continued favorable trends with respect to demand from its clinical customers.
Varian Medical Systems Settles Patent Dispute - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 2:10PM CDT
According to VAR, part of the settlement will be expensed in the financial results of the second quarter while the balance will be recorded as a prepaid royalty in the third quarter of fiscal 2014.
Weakness Seen in AngioDynamics (ANGO): Stock Tumbles 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 7:43AM CDT
AngioDynamics falls 7.8% last trading session, continuing the downtrend
AngioDynamics Q3 Earnings Flat but Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:28AM CDT
ANGO lowered its adjusted EPS guidance for fiscal 2014 to a range of 60 to 63 cents from the prior range of 63 to 67 cents.
Delcath Systems (DCTH) Worth Watching: Stock Soars 20.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:25AM CDT
Delcath Systems was a big mover last session, with shares surging over 20% on the day.
Masimo Reports Encouraging PVI Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 5:40PM CDT
The results demonstrated that MASI's non-invasive PVI parameter helps clinicians optimize fluid administration for abdominal surgical patients under combined general and epidural anesthesia.
Delcath Systems Shares Tank on Stock Split - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 1:50PM CDT
Delcath has been going through a rough patch after it failed to win approval from U.S. Food and Drug Administration (FDA) for its Melblez liver cancer therapy device.
Cepheid (CPHD) Looks Good: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:04AM CDT
Cepheid was a big mover last session, as the company saw its shares rise over 5% on the day.
Delcath (DCTH) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:58AM CDT
Delcath (DCTH) Enters Oversold Territory
Intuitive Surgical (ISRG) Crumbles: Stock Falls by 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:34AM CDT
Shares of Intuitive Surgical fell nearly 7% on the day. This continues the recent trend of the company, as the stock is now trading within the volatile price range of $422.1 to $540.6 in the past one-month time frame.
La Quint Holdings Makes its Debut on the NYSE; Electronics Arts Hires Amy Hennig for Star Wars Project
ACCESSWIRE - Wed Apr 09, 11:44PM CDT
La Quinta Holdings Inc. (NYSE: LQ) - For an in-depth report on La Quinta Holdings Inc. follow: www.BullTrends.com/stockquote/LQ
Varian Medical Systems Closes Velocity Software Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 2:20PM CDT
Post-acquisition, VAR expects its global sales, service and support network to contribute to faster and deeper market penetration for the Velocity product.
Intuitive Surgical Expects Lower Q1 Revs, Shares Dip - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 1:50PM CDT
Per Intuitive Surgical, the deferrals will reduce Systems revenues by roughly $24 million and Instruments and Accessories revenues by $2 million.
Health Care Stocks Technical Coverage -- Research on Valeant Pharma Intl., Alkermes, Delcath Systems, and Acura Pharma
PR Newswire - Wed Apr 09, 7:35AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average edged 0.06% higher to finish the day at 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 3.36% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Alkermes PLC (NASDAQ: ALKS), Delcath Systems Inc. (NASDAQ: DCTH) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). Free technical research on VRX, ALKS, DCTH and ACUR can be downloaded upon signing up at:
Echo Therapeutics Slips to Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 07, 1:50PM CDT
Echo Therapeutics' fourth-quarter reported loss per share more than doubled year over year to $3.9 million or 36 cents.
DexCom Shares Fall on FDA Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 2:30PM CDT
Since the revelation of the warning letter, DexCom's shares dropped 5.7% to close at $41.95 yesterday.
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Teleflex Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 1:50PM CDT
An encouraging guidance, increased M&A activity and stronger operating leverage represent a potential upside for Teleflex going forward.